Cutaneous Adnexal Adenocarcinoma: Genomic Analysis and Successful HER2-targeted Therapy of Metastatic Disease

被引：1
|
作者：
Hirano-Lotman, Yui [1 ]
Ishida, Yoshihiro [1 ]
Endo, Yuichiro [1 ]
Ogawa, Seishi [2 ]
Kabashima, Kenji [1 ]
机构：
[1] Kyoto Univ, Dept Dermatol, Grad Sch Med, 54 Shogoin Kawahara Cho,Sakyo Ku, Kyoto 6068507, Japan
[2] Kyoto Univ, Grad Sch Med, Pathol & Tumor Biol, Kyoto, Japan
来源：
ACTA DERMATO-VENEREOLOGICA | 2023年 / 103卷
关键词：
CHEMOTHERAPY; PERTUZUMAB;
D O I：
10.2340/actadv.v103.9399
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
[No abstract available]
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Predictors of exceptional response to first line HER2-targeted therapy for metastatic breast cancer
    Morganti, Stefania
    Li, Tianyu
    Santos, Katheryn
    Hughes, Melissa
    Priedigkeit, Nolan
    Li, Yvonne
    Lipsyc-Sharf, Marla
    Kirkner, Gregory
    Files, Janet
    Kasparian, Julie
    Grant, Elizabeth
    Gupta, Gunjan
    Curigliano, Giuseppe
    Tolaney, Sara
    Cherniack, Andrew
    Tayob, Nabihah
    Lin, Nancy
    Parsons, Heather
    CANCER RESEARCH, 2024, 84 (09)
  • [22] The efficacy of HER2-targeted agents in metastatic breast cancer: a meta-analysis
    Harris, C. A.
    Ward, R. L.
    Dobbins, T. A.
    Drew, A. K.
    Pearson, S.
    ANNALS OF ONCOLOGY, 2011, 22 (06) : 1308 - 1317
  • [23] Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer
    Nahta, Rita
    Yu, Dihua
    Hung, Mien-Chie
    Hortobagyi, Gabriel N.
    Esteva, Francisco J.
    NATURE CLINICAL PRACTICE ONCOLOGY, 2006, 3 (05): : 269 - 280
  • [24] Novel HER2-targeted therapies for HER2-positive metastatic breast cancer
    Kunte, Siddharth
    Abraham, Jame
    Montero, Alberto J.
    CANCER, 2020, 126 (19) : 4278 - 4288
  • [25] HER2-targeted Therapeutic Strategies for HER2-positive Metastatic Breast Cancers
    Fujii, Teruhiko
    Miwa, Keisuke
    Ushijima, Tomoyuki
    Matsunaga, Mototsugu
    Fukahori, Masaru
    Yuge, Kotaro
    Toh, Uhi
    Iwakuma, Nobutaka
    Takahashi, Ryuji
    Takahashi, Hiroki
    Takenaka, Miki
    Mishima, Mai
    Akagi, Yoshito
    Kage, Masayoshi
    Nakagawa, Shino
    CURRENT CANCER THERAPY REVIEWS, 2014, 10 (03) : 225 - 233
  • [26] Mechanisms of Disease: understanding resistance to HER2-targeted therapy in human breast cancer
    Rita Nahta
    Dihua Yu
    Mien-Chie Hung
    Gabriel N Hortobagyi
    Francisco J Esteva
    Nature Clinical Practice Oncology, 2006, 3 : 269 - 280
  • [27] Genomic Landscape of ERBB2 Alterations in Solid Tumors without an Approved HER2-Targeted Therapy
    Previs, R.
    Ko, H.
    Cooper, M.
    Wallen, Z.
    Nesline, M.
    Pabla, S.
    Hastings, S.
    Strickland, K.
    Zhang, S.
    Sathyan, P.
    Conroy, J.
    Jensen, T.
    Eisenberg, M.
    Caveney, B.
    Reddy, P.
    Severson, E.
    Ramkissoon, S.
    JOURNAL OF MOLECULAR DIAGNOSTICS, 2023, 25 (11): : S132 - S132
  • [28] HER2-targeted therapy in colorectal cancer: a comprehensive review
    Benli, Yeliz
    Arikan, Helin
    Akbulut-caliskan, Ozge
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2025,
  • [29] Late cardiotoxicity related to HER2-targeted cancer therapy
    Isabelle Senechal
    Maria Sol Andres
    Jieli Tong
    Ylenia Perone
    Sivatharshini Ramalingam
    Muhummad Sohaib Nazir
    Stuart D Rosen
    Nicholas Turner
    Alistair Ring
    Alexander R Lyon
    Cardio-Oncology, 10
  • [30] The gut microbiota contributes to the effectiveness of HER2-targeted therapy
    Di Modica, Martina
    Regondi, Viola
    Gargari, Giorgio
    Bonizzi, Arianna
    Arioli, Stefania
    Belmonte, Beatrice
    Tripodo, Claudio
    Guglielmetti, Simone
    Corsi, Fabio
    Triulzi, Tiziana
    Tagliabue, Elda
    CANCER RESEARCH, 2019, 79 (13)
12345